Suppr超能文献

微卫星不稳定性作为II期结肠癌患者的预后因素:已发表文献的荟萃分析

Microsatellite Instability as a Prognostic Factor in Stage II Colon Cancer Patients, a Meta-Analysis of Published Literature.

作者信息

Gkekas Ioannis, Novotny Jan, Pecen Ladislav, Strigård Karin, Palmqvist Richard, Gunnarsson Ulf

机构信息

Department of Surgical and Perioperative Sciences, Umea University, Umea, Sweden

Department of Surgery, Sunderby hospital Lulea, Lulea, Sweden.

出版信息

Anticancer Res. 2017 Dec;37(12):6563-6574. doi: 10.21873/anticanres.12113.

Abstract

BACKGROUND/AIM: The prognostic role of microsatellite instability (MSI) in stage II colon cancer patients remains controversial despite the fact that it has been investigated in a number of studies. Hazard ratios differ considerably among these studies. We performed a meta-analysis to define the significance of MSI in this group of patients.

MATERIALS AND METHODS

Studies indexed in PubMed presenting separate data on MSI status and survival outcomes for stage II colon cancer patients have been analyzed using fixed-effect meta-analysis of hazard ratio (HR) according to the method of Peto.

RESULTS

Analysis was performed on 19 studies including 5,998 patients. A 47.3% of patients received postoperative chemotherapy and included 52.8% males and 47.2% females. Eight studies included some rectal cancer patients although this cohort was not clearly defined in 3 of these. MSI observed in 20.8% (mean) of patients (median 19.9%). HR for overall survival (OS) of MSI vs. microsatellite stable (MSS) tumors for the entire population: 0.73 (95% confidence interval (CI)=0.33-1.65); HR for disease-free survival (DFS):0.60 (95%CI=0.27-1.32). No statistical significant difference was found when studies analyzing MSI with genotyping (MG) and immunohistochemistry (IHC) were compared separately (MG vs. IHC: HR OS 0.45, 95%CI=0.10-2.05 vs. 0.95, 95%CI=0.57-1.58; HR DFS 0.51, 95%CI=0.14-1.85 vs. 0.67, 95%CI=0.26-1.70). However, numerically MSI determination with genotyping shows significantly lower hazard ratios for both DFS and OS. Separate analysis of studies describing colon cancer patients only showed HR OS 0.72 (95%CI=0.31-1.71); HR DFS 0.60 (95%CI=0.27-1.31).

CONCLUSION

No significant relation was found between MSI status and OS or DFS. Routine determination of MSI status to guide postoperative management of stage II colon cancer patients cannot be recommended. New large scale high quality studies are needed to answer this question definitively, since currently analyzed studies vary considerably.

摘要

背景/目的:尽管已经在多项研究中对微卫星不稳定性(MSI)在II期结肠癌患者中的预后作用进行了研究,但其仍存在争议。这些研究中的风险比差异很大。我们进行了一项荟萃分析,以确定MSI在这组患者中的意义。

材料与方法

根据Peto方法,对PubMed中索引的关于II期结肠癌患者MSI状态和生存结果的单独数据的研究进行了固定效应荟萃分析,分析风险比(HR)。

结果

对19项研究进行了分析,包括5998例患者。47.3%的患者接受了术后化疗,其中男性占52.8%,女性占47.2%。八项研究纳入了一些直肠癌患者,尽管其中三项研究对该队列没有明确界定。20.8%(平均)的患者观察到MSI(中位数为19.9%)。整个人群中MSI与微卫星稳定(MSS)肿瘤的总生存(OS)风险比:0.73(95%置信区间(CI)=0.33-1.65);无病生存(DFS)风险比:0.60(95%CI=0.27-1.32)。当分别比较使用基因分型(MG)和免疫组织化学(IHC)分析MSI的研究时,未发现统计学显著差异(MG与IHC:OS风险比0.45,95%CI=0.10-2.05对0.95,95%CI=0.57-1.58;DFS风险比0.51,95%CI=0.14-1.85对0.67,95%CI=0.26-1.70)。然而,从数值上看,基因分型确定MSI在DFS和OS方面的风险比显著更低。仅对描述结肠癌患者的研究进行单独分析显示,OS风险比为0.72(95%CI=0.31-1.71);DFS风险比为0.60(95%CI=0.27-1.31)。

结论

未发现MSI状态与OS或DFS之间存在显著关系。不建议常规测定MSI状态以指导II期结肠癌患者的术后管理。由于目前分析的研究差异很大,需要新的大规模高质量研究来明确回答这个问题。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验